• Explore /
  • Poster
  • / Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Abstract Poster

Authors

null

Hang Su

The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China

Hang Su , Yongping Song , Wenqi Jiang , Xiuhua Sun , Wenbin Qian , Wei Zhang , Yuhuan Gao , Zhengming Jin , Jianfeng Zhou , Chuan Jin , Liqun Zou , Lugui Qiu , Wei Li , Jianmin Yang , Ming Hou , Shan Zeng , Peng Liu , Yuankai Shi , Hui Zhou , Hongli Zuo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03114683

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8034)

DOI

10.1200/JCO.2020.38.15_suppl.8034

Abstract #

8034

Poster Bd #

367

Abstract Disclosures

Similar Posters

First Author: Hang Su

First Author: Yuankai Shi

First Author: Guoliang Shao

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

First Author: Changying Guo